What is the recommended dose of Eliquis (apixaban)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 3, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Recommended Dosing of Eliquis (Apixaban)

The standard dose of Eliquis (apixaban) is 5 mg twice daily for most patients, with a reduced dose of 2.5 mg twice daily for patients who have at least two of the following characteristics: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL. 1, 2, 3

Standard Dosing for Atrial Fibrillation

For patients with nonvalvular atrial fibrillation:

  • Standard dose: 5 mg twice daily
  • Reduced dose: 2.5 mg twice daily if patient has at least two of:
    • Age ≥80 years
    • Body weight ≤60 kg
    • Serum creatinine ≥1.5 mg/dL

Renal Function Considerations

Apixaban dosing based on renal function:

  • CrCl >30 mL/min: 5 mg twice daily (standard dose) or 2.5 mg twice daily (if dose reduction criteria met)
  • CrCl 15-30 mL/min: 5 mg twice daily or 2.5 mg twice daily (if dose reduction criteria met)
  • CrCl <15 mL/min or on dialysis: 5 mg twice daily or 2.5 mg twice daily (if dose reduction criteria met) 2

Other Indications

For DVT/PE treatment:

  • Initial treatment: 10 mg twice daily for the first 7 days
  • Continued treatment: 5 mg twice daily after the initial 7 days 1

For DVT prophylaxis after hip or knee replacement:

  • Dose: 2.5 mg twice daily
  • Duration: 35 days for hip replacement; 12 days for knee replacement 1

For reduction in risk of recurrent DVT/PE:

  • Dose: 2.5 mg twice daily after at least 6 months of treatment 1

Drug Interactions

  • In patients receiving apixaban 5 mg twice daily, reduce dose to 2.5 mg twice daily when combined with strong CYP3A4 and P-glycoprotein inhibitors (e.g., ketoconazole, itraconazole, ritonavir, clarithromycin) 2
  • If patients are already on 2.5 mg twice daily, avoid apixaban use with these inhibitors 2
  • Avoid concomitant use with strong CYP3A4 and P-glycoprotein inducers (e.g., rifampin, carbamazepine, phenytoin, St. John's wort) 2, 3

Administration Guidelines

  • If a dose is missed, take it as soon as possible on the same day and resume twice-daily dosing
  • Do not double the dose to make up for a missed dose 1
  • Apixaban can be taken with or without food 3
  • For patients unable to swallow tablets, apixaban can be crushed and administered via nasogastric tube without altering bioavailability 3

Perioperative Management

For elective procedures:

  • High bleeding risk procedures: Discontinue apixaban 48 hours before procedure
  • Low bleeding risk procedures: Discontinue apixaban 24 hours before procedure
  • Resume apixaban as soon as adequate hemostasis is achieved 2, 1

Important Considerations

  • Clinical data from ARISTOTLE showed that patients with only one dose-reduction criterion who received the standard 5 mg twice daily dose had similar benefits compared to warfarin as those with no dose-reduction criteria 4
  • Regular monitoring of renal function is important, especially in elderly patients 3
  • Apixaban is contraindicated in patients with mechanical heart valves or significant mitral stenosis 3

Remember that premature discontinuation of apixaban increases the risk of thrombotic events, so if anticoagulation needs to be discontinued for reasons other than bleeding, consider coverage with another anticoagulant 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.